Form 4 for DFTX Definium Therapeutics, Inc.

Accepted 2023-06-23 00:00:00 ET · period of report 2023-06-21 · accession 0000899243-23-016417 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-06-23	2023-06-21	DFTX	Bruhn Suzanne Louise	Dir	A - Grant	$0.00	+13.7K	19.6K	+230%	$0
D	2023-06-23	2023-06-21	DFTX	Bruhn Suzanne Louise	Dir	A - Grant	$0.00	+19.2K	27.3K	+238%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2023-06-21	A	A	13,671	$0.00	19,623	D	—	—	(F1) These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Common Share of the Issuer. The RSUs shall vest in four (4) equal quarterly installments from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. (F2) On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the" Reverse Stock Split"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split.
2	Derivative	Stock Option (Right to Buy)	2023-06-21	A	A	19,203	$0.00	27,267	D	$3.61 · — to 2033-06-20	19,203 Common Shares	(F2) On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the" Reverse Stock Split"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split. (F3) The shares underlying the option shall vest in twelve (12) equal monthly installments starting from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.